Given the known epidemiologic link between IPF and lung cancer (Abu Qubo et al., 2022), and shared pathogenic features such as senescence, chronic injury, and aberrant epigenetic reprogramming (Zhan et al., 2025), it is plausible that SPARC silencing may participate in a common disease axis. Here, SPARC is linked to lung carcinoma.